Skip to main content

$0.012 (0%)

High

$0.01

Low

$0.01

Trades

21

Turnover

$70,215

Volume

5,851,219
30 June 2023 at 4:10pm
Register to track OSL and receive email alerts.
Subject
OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

OSL Ann: PanCO Clinical Study on OncoSil Published in ESMO Open

OSL Ann: Initial Director's Interest Notice - Prof. Ricky Sharma

OSL Ann: Jobkeeper Payments Notification

OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

OSL Ann: Change of Director's Interest Notice - Mr Nigel Lange

OSL Ann: Final Director's Interest Notice - Mr Michael Bassett

OSL Ann: Final Director's Interest Notice - Dr Chris Roberts

OSL Ann: Notification regarding unquoted securities - OSL

OSL Ann: Issue of Performance Rights

OSL Ann: Final Director's Interest Notice

OSL Ann: Results of the OncoSil 2021 Annual General Meeting

OSL Ann: 2021 AGM CEO Presentation

OSL Ann: 2021 AGM Chairman's Address

OSL Ann: Resignation of Director - Dr Roger Aston

OSL Ann: Prof. Ricky Sharma appointed to the Board of OncoSil

OSL Ann: Receipt of $1.077m R&D Tax Incentive Refund

OSL Ann: Notice of General Meeting/Proxy Form

OSL Ann: Change of Director's Interest Notice

OSL Ann: Appendix 4G and Corporate Governance Statement

OSL Ann: Appendix 4E Announcement

OSL Ann: Appendix 4E and Annual Report

OSL Ann: Cancellation of shares under the Employee Share Plan

OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

OSL Ann: Initial Director's Interest Notice

OSL Ann: Otto Buttula appointed to the Board of OncoSil

OSL Ann: OncoSil TGA regulatory update

OSL Ann: Cancellation of loan funded shares

OSL Ann: Change of Director's Interest Notice

OSL Ann: OncoSil receives regulatory approval from Hong Kong

OSL Ann: Appendix 4C - quarterly

OSL Ann: Change of Registered Office and Principal Place of Business

OSL Ann: Business update call transcript

OSL Ann: Half Yearly Report and Accounts

OSL Ann: Half-Yearly Report Results

OSL Ann: OncoSil Investor Update

OSL Ann: Business Update - Conference Call Notification

OSL Ann: Appointment of Chief Medical Officer & Medical Affairs Head

OSL Ann: Appendix 4C - quarterly

OSL Ann: Cancellation of shares under the Employee Share Plan

OSL Ann: Initial Director's Interest Notice

OSL Ann: Appointment of Chief Executive Officer

OSL Ann: OncoSil FY21 half yearly review

OSL Ann: Final Director's Interest Notice

OSL Ann: Change of Director's Interest Notice

OSL Ann: Change of Director's Interest Notice

OSL Ann: Cancellation of shares under the Employee Share Plan

OSL Ann: Termination of Mr Daniel Kenny as Chief Executive Officer

OSL Ann: Change of Director's Interest Notice

OSL Ann: Appendix 2A

Register to track OSL and receive email alerts.

Similar Companies

ADO
BPH
CTE
GSS
GTG
MEM
PAL
PIQ